Latest Share Chat

ValiRx Share News (VAL)

ValiRx Information

Buy VAL Shares
Add VAL to Watchlist
Add VAL to Alert

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes

Get Live Data

Share Price: 3.20

Bid: 0.00

Ask: 0.00

Change: 0.00 (0.00%)

Spread: 0.20 (6.452%)

Open: 0.00

High: 0.00

Low: 0.00

Prev. Close: 3.20

Last checked at -

ValiRx Delays Annual Results Amid Covid-19 Pandemic

Mon, 08th Jun 2020 15:39

(Alliance News) - ValiRx PLC on Monday said that it will be unable to post its annual results before this month's deadline due to the Covid-19 pandemic.

The life sciences had until June 30 to post its 2019 results, under usual AIM rules, but has applied for an extension.

It means ValiRx now has until September 30 to reports its results.

Shares in the company were 0.2% higher at 7.14 pence each in London on Monday afternoon.

By Eric Cunha; ericcunha@alliancenews.com

More News

1 Apr 2020 12:12

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

30 Mar 2020 16:41

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

10 Mar 2020 11:42

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

4 Mar 2020 17:25

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

17 Feb 2020 12:48

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

10 Feb 2020 16:00

UK Shareholder Meetings Calendar - Next 7 Days

14 Jan 2020 14:50

ValiRx signs letter of intent in a bid to fund VAL401

(Sharecast News) - Clinical-stage biotechnology company ValiRx updated the market on its subsidiary joint venture, ValiSeek, and its cancer therapeutic, VAL401 on Tuesday.

14 Jan 2020 11:08

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

6 Jan 2020 09:59

ValiRx Raises GBP200,000 To Progress Product Development

16 Dec 2019 10:17

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

28 Nov 2019 16:13

ValiRx granted US patent for 'VAL201' compound

(Sharecast News) - Clinical stage biotechnology company ValiRx announced on Thursday that the US Patent and Trademark Office has granted patent number 10,400,008, titled 'Modulators Of The SRC-Kinase Activity For Preventing Or Treating Metastatic Cancer', to its lead therapeutic compound 'VAL201'.

28 Nov 2019 15:57

Latest Share Chat

ValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Raises GBP200,000 To Improve "Extremely Weak" Capital Position

ValiRx "Critically Short" Of Working Capital, In Funding Discussions

ValiRx Still Faces Going Out Of Business; Proposes New Share Plan

ValiRx Investors Seek Removal Of Directors Morris And Vainikka

ValiRx's Future In Doubt As Investors Say No To Capital Reogranisation

UK Shareholder Meetings Calendar - Next 7 Days

ValiRx signs letter of intent in a bid to fund VAL401

ValiRx Joint Venture Partner Enters Agreement For VAL401 Funding

ValiRx Raises GBP200,000 To Progress Product Development

ValiRx Reveals "Clear Impact" Of VAL201 On Prostate Cancer Patients

ValiRx granted US patent for 'VAL201' compound

ValiRx Granted "Key" US Patent Protection For VAL201 Cancer Treatment

ValiRx Raises GBP350,000 Through Placing To Progress Clinical Trials

ValiRx Reports Narrowed Loss In First Half As Expenses Reduce

ValiRx Receives GBP423,000 Research & Development Credit From UK HMRC

Latest Share Chat

ValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ValiRx Delays Annual Results Amid Covid-19 Pandemic

Login to your account

Quickpicks are a member only feature

Login to your account